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PENILAIAN KE ATAS STATUS METILASI O6-METHYLGUANINE-DNA-
METHYLTRANSFERASE (MGMT) GEN DI KALANGAN PESAKIT 




Banyak kajian telah membuktikan bahawa memahami peranan bio-penanda telah 
meningkatkan persepsi semasa berkenaan genesis glioma, penilaian ramalan dan 
perancangan rawatan untuk pesakit. Sebagai contoh, pengenalpastian status metilasi 
promoter gen O6-methylguanine-DNA-methyltransferase (MGMT) yang mengekod 
MGMT, iaitu sejenis protein yang terlibat dalam aktiviti pembaikan DNA, dapat 
meningkatkan keberkesanan penjagaan piawai semasa glioma, apabila baru-baru ini, 
status metilasi telah diperkenalkan sebagai bio-penanda untuk stratifikasi rancangan 
rawatan. Bagi lebih memahami peranan MGMT, kami telah menilai status metilasi 
promoter MGMT pesakit glioma di Hospital USM. Dalam kajian ini, 41 sampel tisu 
glioma yang yang disimpan secara parafin-terbenam (FFPE) telah diperolehi 
berdasarkan penggredan dari Gred II (n = 11), III (n = 10) dan IV (n = 20). Selepas itu, 
pengekstrakan DNA dan status metilasi telah disahkan melalui kaedah tindak balas 
berantai polimerase metilasi-spesifik (MSP) dengan menggunakan dua pasang primer 
khusus mensasarkan unmethylated (UM) dan methylated (M) di dalam gen MGMT, 
masing-masing. Keputusan MSP dikenalpasti mengandungi intratumoral 
heterogeneity yang tinggi dalam semua gred tumor. 9.1% daripada Gred II glioma 
adalah M manakala selebihnya 90.9% adalah kombinasi UM dan M. Lebih-lebih lagi, 
Gred III glioma menunjukkan kedua-duanya adalah 50% M dan kombinasi 50% 
masing-masing UM dan M. Gred IV glioma menunjukkan 15% UM, 30% M dan 55% 
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kombinasi UM dan M. Walau bagaimanapun, analisis menggunakan Fisher’s exact 
test mendapati tiada kaitan statistik yang signifikan antara status metilasi MGMT 
dengan mana-mana parameter klinikopatologi yang diuji seperti gred tumor, umur, 
jantina dan bangsa pesakit (p > 0.05). Kesimpulannya, kajian ini mendapati metilasi 
MGMT berlaku dengan kadar yang kerap di dalam pesakit glioma di Hospital USM, 
tanpa mengira gred tumor, umur, jantina dan bangsa. Lebih-lebih lagi, penemuan 
status kombinasi MGMT dalam semua gred glioma mencadangkan kehadiran 
intratumoral heterogeneity di dalam tumor tersebut. Selain menunjukkan intratumoral 
diversity, ia juga mungkin menggambarkan cabaran yang mungkin dihadapi dalam 
usaha menentukan rawatan secara peribadi berdasarkan status epigenetik MGMT.  
 





THE EVALUATION OF O6-METHYLGUANINE-DNA-
METHYLTRANSFERASE (MGMT) GENE METHYLATION STATUS 




Growing evidences demonstrate the understanding of the biomarkers and it 
significantly increased our current perception of gliomagenesis, prognostic evaluation, 
and treatment planning for the patients. For instance, identification of the promoter 
methylation status of O6-methylguanine-DNA-methyltransferase (MGMT) gene 
encodes MGMT, a protein with DNA repair activity may improve the efficacy of 
current standard care in glioma as the methylation status has been recently introduced 
to be a predictive biomarker for stratification of the treatment plan. To further 
understand the roles of MGMT, we aimed to evaluate the MGMT promoter methylation 
status of glioma patients in Hospital USM. In this study, 41 samples of paraffin-
embedded glioma tissue (FFPE) were obtained based on their grading from Grade II 
(n = 11), III (n = 10) and IV (n = 20). Subsequently, DNA extraction and methylation 
status was validated by methylation-specific PCR (MSP) method using two pairs of 
primers specifically targeting the unmethylated (UM) and methylated (M) regions of 
the MGMT gene, respectively. MSP results identified high intratumoral heterogeneity 
of the samples in all grades of the tumours. In Grade II glioma, 9.1% were M and 
90.9% were combination of UM and M. Moreover, Grade III glioma indicated 50% M 
and combination of UM and M, respectively. Besides, Grade IV glioma exhibited 15% 
were UM, 30% were M and 55% were both UM and M. Nevertheless, analysis using 
Fisher’s exact test found no statistical association of the MGMT methylation status 
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with any of the tested clinicopathological parameters such as tumour grade, age, 
gender, and race of the patients (p > 0.05). In conclusion, this study found frequent 
MGMT methylation, regardless of the tumour grade, age, gender and race of the glioma 
patients at Hospital USM. Moreover, the occurrence of MGMT combination status in 
all grades of gliomas suggested intratumoral heterogeneity of the tumour. Besides 
imparting intratumoral diversity, it may also indicate possible challenges in defining 
personalized treatment based on the epigenetic status of MGMT.  
 












Glioma is a type of brain tumour that begins in glial cells within the brain or 
spinal cord. It is the most predominant type primary brain tumours which can be found 
in adults which comprises of 30% to 40% of all intracranial tumours where its utmost 
prevalence are between the ages of 40 and 65 (Schneider et al., 2010). According to 
World Health Organization (WHO) 2016 classification, gliomas were stratified from 
Grade I to Grade IV which can be grouped into two categories such as low-grade and 
high-grade gliomas (Louis et al., 2016). Additionally, in relation to the classification, 
Grade I and II, and also Grade III and IV are termed as low-grade gliomas (LGGs) and 
high-grade gliomas (HGGs) respectively. 
 
Gliomas with the tendency of growing and infiltrating normal brain tissue 
characteristics often complicates the surgical procedures and sometimes makes it 
impossible to remove the tumour. As such, low-grade gliomas which often occur in 
young or healthy patients have a slow-moving course with extended survival rate 
compared to high-grade gliomas. Clinical manifestation chiefly holds responsible for 
prognosis information for treatment plans. For example, seizures are common 
symptom that makes up to 80% of patients, also changes of behaviour, focal 
neurological loss, increasing intracranial pressure like headache or papilledema. 
However, it was also reported that some patients being asymptomatic adds on issues 
for treatment schemes (Forst et al., 2014; Pouratian et al., 2007). Although the 
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histopathologic investigation of tissues was set to be gold standard for diagnosis and 
grading of LGG with imaging methods, more new advanced imaging techniques 
needed (Forst et al., 2014).  
 
On top of that, HGGs are the recurrent unit which accounts over 50% of the 
primary malignant brain tumours mainly in older ages. Among the concerns in HGGs, 
the same treatment plans or even research procedures applied for both Grade III and 
IV which reports as one of the drawback despite of the understanding of general 
molecular machinery of HGGs, surgeries, radiation or chemotherapy as well as 
imaging techniques that has been applied till date. Yet, the overall prediction especially 
for treatment plans still remains a challenge (Brown et al., 2006; Mirimanoff, 2014). 
 
Hence, it is high-priority to find a new therapeutic approach where it can be 
potentially used as new modality as the failure to identify the specific molecular 
identity of the tumour can be resulting in an ineffective treatment and may worsen the 
prognosis (Ray et al., 2014). From a clinical point of view, a biomarker should be 
highly sensitive and specific in providing information relevant for diagnosis, prognosis 
or therapy of a disease. Concerning about the approaches, MGMT gene has been shown 
to have association with improved outcome in glioma and can be a predictive marker 
of sensitivity to alkylating agents. The methylation status of the MGMT promoter has 
been identified as a strong and independent predictive factor of favourable survival in 
glioblastoma patients undergoing chemotherapy with alkylating agents where it shows 
35%–45% of malignant gliomas (WHO grades III and IV) and in about 80% of WHO 
grade II gliomas (Hegi et al., 2005a; Ahluwalia, 2011). The range of median survival 
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of the patients with methylated MGMT promoter was 21.7 months compared with 12.7 
months for patients without (Christians et al., 2012a). 
 
Furthermore, MGMT methylation status also provides insight as a molecular 
biomarker in which it aids in understanding of glioma development. It increases the 
patients’ prognostic profiling and help for a possible personalised treatment plan which 
helps in clinical relevance (Thon et al., 2013). Therefore, to address this issue, 
evaluation of MGMT methylation status and its association with the 
clinicopathological data of the glioma patients at Hospital Universiti Sains Malaysia 







2.1 Brain tumours 
2.1.1 Classification of brain tumours 
 
Brain tumours are defined as an abnormal cell growth in the brain. It can be 
classified as benign or malignant type, as stated by the National Cancer Institute (NCI). 
American Brain Tumour Association reported that benign tumour occurs in people of 
all ages while malignant types are more prevalent among adults compared to children. 
Apart from that, they can also be stratified as primary brain tumour which originates 
and stays in the brain while secondary brain tumour referred as the cancer that begins 
somewhere else in the body and spreads to the brain. 
 
Based on histogenesis concept, the classification of brain tumours has been made 
where it was classified according to their microscopic similarities with different 
putative cells of origin and their recognised levels of differentiation for the past century 
(Louis et al., 2007). The histological characterisation was based on light microscopic 
features in hematoxylin and eosin-stained sections, immunohistochemical expression 
of lineage-associated proteins and ultrastructural characterisation. For instance, the 
tumours of an astrocytic phenotype distinguished separately from oligodendroglial 
phenotype although they were clinically similar or unrelated as per classified by World 
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Health Organization (WHO) Classification of Tumours of the Central Nervous System 
2007 (2007 CNS WHO). Some studies clarified that the classification of tumours were 
based on tumourigenesis at genetic level as well as with some unusual brain tumour 
entities. However, this information could not be used to define specific entities but 
conventional histology has proven the prognostic data within the diagnostic categories 
(Louis et al., 2007).  
 
Recently, WHO classifies the CNS tumours by using molecular parameters in 
addition to histology to define many tumour entities, thus formulating a concept for 
how CNS tumour diagnoses should be structured in this molecular era as shown in 
Figure 2.1. As such, the 2016 CNS WHO demonstrates the classification which 








Figure 2.1 Classification approach in brain tumours (Adapted and modified from 




Histology of the 
Tumour 





Table 2.1 The 2016 World Health Organization (WHO) Classification of Tumours of 




Diffuse astrocytic and oligodendroglial tumours 
Diffuse astrocytoma, IDH-mutant II 
Anaplastic astrocytoma, IDH-mutant III 
Glioblastoma, IDH-wildtype IV 
Glioblastoma, IDH-mutant IV 
Diffuse midline glioma, H3 K27M-mutant IV 
Oligodendroglioma, IDH-mutant and 1p/19q codeleted II 
Anaplastic oligodendroglioma, IDH-mutant and 1p/19q 
codeleted 
III 
Other astrocytic tumours 
Pilocytic astrocytoma I 
Subependymal giant cell astrocytoma I 
Pleomorphic xanthoastrocytoma II 
Anaplastic pleomorphic xanthoastrocytoma III 
Ependymal tumours 
Subependymoma` I 
Myxopapillary ependymoma I 
Ependymoma  II 
Ependymoma, RELA fusion-positive II or III 
Anaplastic ependymoma III 
Other gliomas 
Angiocentric glioma I 
Chordoid glioma of third ventricle II 
Choroid plexus tumours 
Choroid plexus papilloma I 
Atypical choroid plexus papilloma II 
Choroid plexus carcinoma III 
Neuronal and mixed neuronal-glial tumours 
Dysembryoplastic neuroepithelial tumour I 
Gangliocytoma  I 
Ganglioglioma I 
Anaplastic ganglioglioma  III 
Dysplastic gangliocytoma of cerebellum (Lhermitte-Duclos) I 
Desmoplastic infantile astrocytoma and ganglioglioma I 
Papillary glioneuronal tumour I 
Rosette-forming glioneuronal tumour I 
Central neurocytoma II 
Extraventricular neurocytoma II 
Cerebellar liponeurocytoma II 
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Tumours of pineal region 
Pineocytoma I 
Pineal parenchymal tumour of intermediate differentiation II or III 
Pineoblastoma IV 
Papillary tumour of pineal region II or III 
Embryonal tumours  
Medulloblastoma (all subtypes) IV 
Embryonal tumour with multi-layered rosettes, C 19MC-altered IV 
Medulloepithelioma IV 
CNS embryonal tumour, NOS IV 
Atypical teratoid/rhabdoid tumour IV 
CNS embryonal tumour with rhabdoid features IV 
Tumours of the cranial and paraspinal nerves 
Schwannoma I 
Neurofibroma I 
Perineurioma  I 
Malignant peripheral nerve sheath tumour (MPNST) II, III or IV 
Meningiomas 
Meningioma  I 
Atypical meningioma II 
Anaplastic (malignant) meningioma III 
Mesenchymal, non-meningothelial tumours 
Solitary fibrous tumour/haemangiopericytoma I, II or III 
Haemangioblastoma I 
Tumours of the sellar region 
Craniopharyngioma  I 
Granular cell tumour  I 
Pituicytoma I 
Spindle cell oncocytoma I 
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As for tumour grading that has been classified by WHO CNS 2016, there are 
four types of gliomas which comprises of grade I, II, III and IV.  
 
Table 2.2 WHO Brain Tumour Grades (Adapted from Louis et al., 2016) 






























































































As denoted in the table above, low-grade gliomas which includes grade I and II 
are non-malignant while grade III and IV are malignant ones also known as high-grade 
gliomas. Grade I are commonly correlated with long-term survival, as their nature of 
growing steadily and normal appearance via microscope makes the surgery alone as 
an effective treatment whereas the form of grade II tumours are faintly abnormal under 
the microscopic view. Similarly, some spreads as higher grade tumour to nearby 
normal healthy tissues and reoccur although they grow slowly. As for grade III which 
are known to be malignant, often reoccur as grade IV, and are actively replicating 
anomalous cells which can be grown neighbouring the normal tissues. Grade IV 
tumours are the most malignant tumours that proliferates fast into normal healthy brain 
tissues. They have an unusual, peculiar appearance, and have deceased cells in their 
core, also forms new blood vessels which aids in their rapid growth. The most common 
example of grade IV tumour is the glioblastoma multiforme. 
 
In brief, molecular guidelines have been used to lay the foundations of brain 
tumour diagnosis for the first time as the 2016 CNS WHO represents useful step 
forward which has been descended from 2007. The 2016 CNS WHO incorporates the 
objective molecular data in classifications as an intermediate stage which allows the 








2.1.2 Symptoms of brain tumour 
 
In general, the commonly first noticed symptom of brain tumour is an increased 
intracranial pressure. Also, tumours with extensive peritumoral swelling which is also 
known as oedema naturally leads to an elevated intracranial pressure which rendered 
into headaches, vomiting (with or without nausea), dilation of pupil on the lesion side 
(anisocoria), altered state of consciousness, for example, coma and somnolence, 
papilledema are to be noticed as primary symptoms (Davies and Clarke, 2004). An 
increase of an intracranial pressure may result in brain herniation of certain parts of 
the brain. For instance, cerebellar tonsils or temporal uncus which results in lethal 
brainstem compression while it causes an increase in the diameter of the skull and 
bulging of fontanelles in very young children.  
 
Salander classified the symptoms as ‘trigger’ symptoms which an early phase 
symptoms faced by the patients will be referred to the physicians for consultations. 
Hence, he grouped them into four categories such as headache, seizure, motor or 
sensorial dysfunction and mental dysfunction (Salander et al., 1999). 
 
A. Headache  
It was reported to be more persistent and more intense than a normal headache 
where some accompanied by vomiting. The mean duration of this symptom 






5 months which is in range of 0.5 to 2 years was the mean duration of this 
symptom.  
 
C. Motor or sensorial dysfunction 
These symptoms are less important in this group of patients compared to 
headache and seizure group. The mean duration of this symptom was less than 
a month (range 0-5 months). 
 
D. Mental dysfunction 
Some patients were reported to have this symptom who later turned out to be 
psychotic as well.  
 
Moreover, the clinical signs and symptoms of brain tumours can be general or 
focal which means general symptoms such as headache and seizure. This is due to an 
increased intracranial pressure while focal symptoms are like unilateral weakness or 
personality changes due to pressure or impairment in specialised regions where the 
initial symptoms of brain tumours are often focal. In additional to that, it usually 
progresses to generalised symptoms as the tumour increases in size and spreads which 















TUMOUR LOCATION NEUROLOGICAL SIGN 
Frontal lobe Dementia, changes in personality, gait 
disturbances, generalised/focal seizures, 
expressive aphasia 
Parietal lobe Sensory loss, receptive aphasia, 
hemianopia, spatial disorientation 
Temporal lobe Behavioural changes, quadrantanopia, 
complex partial/generalised seizures 
Occipital lobe Contralateral hemianopia 
Thalamus Behavioural changes, contralateral 
sensory loss, language disorder 
Cerebellum Ataxia, dysmetria, nystagmus 
Brain stem Ataxia, nystagmus, hemiparesis, 
papillary abnormalities, cranial nerve 
dysfunction, autonomic dysfunction 
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Another study by Chandana (2008) revealed that headache accompanied by 
nausea and vomiting usually associated with tumour where some patients with brain 
tumour often report a bifrontal, tension-type headache. Additionally, there was a cause 
of an evaluation for brain tumour with a chronic, persistent headache with nausea, 
vomiting, seizures, alteration in headache pattern, neurologic symptoms or even with 
worsening of locations (Perkins and Liu, 2016). On top of that, it was also reported 
that cognitive dysfunction which includes language, attention and executive 
functioning is one of the incidental symptoms of brain tumour (Taphoorn and Klein, 
2004). 
 
In psychiatric view of brain tumour, it may present together with mood 
symptoms, psychosis, memory issues, changes in personality, anxiety or anorexia 
which may complicates the clinical image where the signs generally do not have any 
localizing values, hence, it suggested a work up with neuroimaging prior to diagnosis 
(Madhusoodanan et al., 2015). According to Keschner (1938), he reported that 78% of 
530 patients in his study displayed psychiatric symptoms but only 18% of them 
presented as the first clinical indication of brain tumour. Besides that, a lesion in one 
region the brain expresses a profusion of symptoms which also depends on the activity 
of the repressed neuronal foci due to the neuronal connection of the brain which as 







2.1.3 Risk factors of brain tumour 
 
Risk factor in another word is the components that affect the chances of getting 
diseases. Thus, different diseases have different risk factors. Epidemiologic studies 
offered a whole understanding of any diseases including prevention and treatment of 
the diseases. However, epidemiologic studies for brain tumour with respect to risk 
factors have been mostly inconclusive due to various factors (Florian et al., 2013).  
 
a) Age and race 
It was reported that more Caucasians are affected than African or Asian 
descendants and this has been more accurate for all ages (Ohgaki and Kleihues, 
2005). As for age, the developed countries have higher rate as such it was 
reported that age between 75 and 84 years has peak occurrence of brain tumour 
(Ostrom et al., 2015). 
 
b) Gender 
Gender is now concurred in most of the studies as the fact that females showed 
less incidence of brain tumour compared with males. This was supported by 
the data from CBTRUS where brain tumour showed a higher rate in males than 
female (7.17/100,000 person-years vs. 5.07/100,000 person-years) (Ostrom et 
al., 2015). In general, females retain longer survival rate in most types of 
tumour. This fact was proved with an experimental research where female rats 
were transplanted with the brain tumours, as a result, the female rats possessed 
a slow growth rate and a longer survival rate (Florian et al., 2013). 
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c) Family history and genetic factors 
Family history accounts a small proportion of brain tumours which also reflects 
genetic factors (Crump et al., 2015). A study showed that the existence of 
family member with brain tumour with genetic factors involved proclaimed to 
have higher incidence of brain tumours (Florian et al., 2013; Malmer et al., 
2003). However, brain tumours with genetic factors are yet to be clarified 
(Bondy et al., 2008). The above statement assisted where the study showed 
non-significant increased rate of brain tumour with epidemiologic factors as it 
is not well defined and the rate of those genetically transmitted diseases 
associated with brain tumours like neurofibromatosis and familial cancer 
syndromes (e.g., Li-Fraumeni) (Ommi, 2015).  
 
2.2 Gliomas  
 
According to the cell origins as well as histopathological indication, where it 
aids in the prediction of the tumour behaviour, central nervous system (CNS) tumours 
are defined. Gliomas as such are neuroepithelial tumours which originated from glial 
cells which is a supporting cells of CNS (Louis et al., 2007). WHO categorises the 
tumour classification system accordingly from Grade I (lowest grade) to Grade IV 
(highest grade). On the other hand, gliomas are also classified in two main groups 
known as low grade gliomas (LGGs) and high grade gliomas (HGGs). LGGs which 
includes Grade I and II while HGGs includes Grade III and IV. They are generally 
classified based on their histopathological characteristics such as anaplasia, 
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cytological atypia, activity of mitosis, microvascular proliferation and necrosis (Louis 
et al., 2016).  
 
2.2.1 Clinical and pathological characteristics 
 
LGGs often occur in young patients which are also a distinctive group of primary 
brain tumours. In Grade I tumours, they contain none of the aforesaid histologic 
attributes while in Grade II tumours, they are specified by the existence of cytological 
atypia alone. The histopathology characteristics were determined by using 
Hematoxylin and Eosin (H&E) staining. For instance, diffuse astrocytomas have well-
altered fibrillary or gemistocytic neoplastic astrocytes on a loose matrix, while 
oligoastrocytomas consist of dispersed infiltrating tumours along with the concoction 
of oligodendroglial and astrocytic type of cells and oligodendrogliomas which 
contains cells with even-looking nuclei and perinuclei are infiltrating tumours which 
are often called as “fried egg” appearance (Forst et al., 2014; Louis et al., 2016). Into 
the bargain, Grade I has low proliferative rate compared to Grade II which also has 
low proliferative rate despite reoccur often is infiltrative in nature generally. 
Furthermore, the tendency of Grade II of progressing to higher grades supports the 
evident that Grade II does recur. This can be seen when low-grade diffuse 
astrocytomas change to anaplastic astrocytomas and glioblastoma. Similarly, it 





HGGs are the gliomas that grow and spread rapidly which usually found in adults 
and 8-12% in paediatrics (Bondy et al., 2008). HGGs which generally occur from 
LGGs are aggressive in nature. Grade III often represent as an intermediate stage in 
the development from diffuse astrocytomas to glioblastomas in terms of both 
histological and molecular characteristics. The most common Grade III type is 
anaplastic astrocytomas. Besides that, Grade IV which is highly proliferative does 
infiltrate the neighbouring tissues. The aggressiveness characteristic of Grade IV also 
depends on high frequency of abnormality, nuclear hyperchromatosis and necrotic 
areas (Urbańska et al., 2014). The common clinical characteristic that can be found in 
gliomas are headaches, ataxia, visual interference and seizures (Schneider et al., 2010; 




Gliomas have significant impact on the patients as the patients with gliomas have 
a poor prognosis, in which LGGs are often curable with surgery while HGGs are the 
complex ones with low survival rate and high mortality. It was reported that there is a 
limited clinical epidemiological data of glioma patients due to the high mortality, low 
incidence and heterogeneous infection with variety of tumour subtypes (Krogh 
Rasmussen et al., 2017). The Central Brain Tumour Registry of the United States 
(CBTRUS) proclaimed that gliomas report for 32% of primary CNS tumours in which 
17% of them are astrocytic tumours and 28% of them are glioblastomas in young adults 
with age in the range of 20-34 years old (Ostrom et al., 2015). However, the incident 
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rate in LGGs is lower compared to HGGs. The reason for this inconsistency is 
uncertain.  
 
The incident that was reported by the distribution of glioma by specific histology 
showed that glioblastoma comprises the major percentage of gliomas compared to 
others (Forst et al., 2014; Ostrom et al., 2015) as shown below in Figure 2.2.  
 
Figure 2.2 Distribution of CNS gliomas by Histology Subtypes (Adapted from Ostrom 
et al., 2015) 
 
The incident rate of gliomas is generally higher in men compared to women in 
Denmark population (Ohgaki and Kleihues, 2005; Rasmussen et al., 2017). Moreover, 
it was reported by Malaysian Cancer Statistics-Data and Figure Peninsular Malaysia 
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2006 that the incident rate of gliomas by age per 100,000 population was between 60-
69 years old as shown in Table 2.4. 
 
Table 2.4 Brain tumour Age specific Cancer Incidence per 100,000 population 
(Malaysian Cancer Statistics 2006) 
 
 
2.2.3 Current Treatment Strategies 
 
Treatment approaches for glioma patients usually will be carried out depending 
on the type, size grade and location of the tumour. The initial stage of treatment was 
surgical or resection of tumour tissues. Before attaining total resection, biopsy was 
done to obtain pathological diagnosis (Davis, 2016). Besides that, LGGs primarily 
affect young adults while HGGs affect adults and older patients. In comparison with 
grade III and IV gliomas, LGGs usually have more favourable prognosis. In LGGs, 
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surgeries were conducted to confirm histology of lesion’s nature, improving the 
neurological condition of the patients, minimize the tumour growth risks, preventing 
the malignant transformation as well as seizures control (Van den Bent, M. J et al., 
2012). Most of the studies demonstrated that size of LGGs is an independent 
prognostic factor and has contrary association between the resection and lesion size.  
 
For instance, the poor defined deep lesions usually are not considered for 
resection, hence, because of this various growth pattern of gliomas, a molecular 
background study is anticipated (Pignatti F et al., 2002) such as MGMT promoter 
methylation, IDH 1 mutations, 1p/19q co-deletion. Other than that, radiation therapy 
was also used as a treatment for LGGs where it showed some improvement in 
progression free survival from 3.4 to 5.3 years. The study also suggested that the 
neurological function and seizure has been improved after the exposure of the radiation 
(Shaw E et al., 2002). As for chemotherapy role in LGGs, it is still incompletely 
understood but radiation and chemotherapy found to have benefit at initial stage of 
diagnosis. Surgeries, radiation and chemotherapy are still considered as an initial 
treatment as well as treatment after recurrence in HGGs. It is believed that the 
combination with radiation and surgery, chemotherapy may revamp the survival rate 
in the patients with high grade of gliomas. Unlike for paediatrics, surgeries and 
radiation are regular approach and a better prognosis for children compared to adults. 
Moreover, the common and widely used drug is Temozolomide (TMZ) in clinical 
studies. Besides TMZ, chloroethyl-cyclohexyl nitrosourea (CCNU or lomustine), 
vincristine, and prednisone used during postsurgical and been dominant to the standard 
surgical treatment and radiotherapy (MacDonald et al., 2011). 
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In recent days, due to the advanced scientific knowledge as well as research of 
molecular genetics, it has led to the evolution of targeted drug therapy in gliomas. For 
instance, bevacizumab (Avastin) has been given intravenously to stop the new blood 
vessels formation which eventually cuts off the blood supply to the tumour and kills 
the tumour. It was also supported by the evident from angiogenesis inhibition with 
bevacizumab in combination with irinotecan which had showed positive results at 
initial stage (Schneider et al., 2010).  
 
Another application of therapeutic approach that was carried out recently is the 
antisense oligonucleotides directed against TGF-β2, a highly immunosuppressive 
cytokine, through a catheter that is surgically inserted into the tumour (Hau et al., 
2007).  
 
Another study by Chandramohan and his colleagues (2012) demonstrated that 
usage of virus like oncolytic viruses also has been used as one of the treatment at the 
pre-clinical and clinical stages. This study proves that the concept of targeting cancer 
cells using an antibody-toxin which was investigated in 1970 by Moolten and 
Cooperband 1970. This was also supported by (Todo et al.,2012) which has 
demonstrated the same concept by using exotoxins. Immunotherapies involving 
vaccines showed long term survival in both adults and children with newly diagnosed 





2.3 DNA Methylation 
 
DNA methylation is a hereditary epigenetic mark which involves the transfer of 
methyl group to the C-5 position of the cytosine ring of DNA by DNA 
methyltransferases (DNMTs) (Jin et al., 2011). DNA methylation often occurs at 
cytosines in any condition of the genome in mammals (Lister et al., 2009). Besides 
that, DNA methylation contributes to decoding of human epigenome (Kulis and 
Esteller, 2010). It is also serves as a biomarker for patients’ prognosis (Shinawi T et 
al., 2013). DNA methylation is important in normal development in mammals but it 
causes diseases in methylation defects. Histones which was wrapped by double-
stranded DNA forms chromatin in which the state of chromatin can be either “active” 
or “silent” based on the interaction between promoters or enhancers of the genes and 
transcriptional factors. The mechanism is not clear by which the gain of methyl groups 
in CpG sites knocks down the gene expression (Cheung et al., 2009). Figure 2.3 below 
shows the mechanism of DNA methylation in normal and cancer cell. 
 




2.3.1 Molecular basis of DNA methylation  
 
Generally, DNA methylation acts as a gene expression regulator in which it 
becomes decisive for development of cancer, mainly in higher eukaryotes. To date, 
three types of DNA methyltransferase have been pinpointed such as DNMT1, 
DNMT3A and DNMT3B. All those three DNA (cytosine-5)-methyltransferases helps 
in the establishment of DNA methylation pattern. Each genes plays a critical role in 
initiation and maintenance of DNA methylation. DNMT1 plays a role for the 
conservation of cytosine methylation. Moreover, DNMT3A involves in parental 
imprinting (Kimura and Shiota, 2003). All the above genes transfer methyl group from 
S-adenosyl-L-methionine to cytosines in CpG dinucleotides (Hermann et al., 2004; 
McCabe et al., 2009).  
 
2.3.2 Types of DNA methylation 
 
DNA methylation can be divided into hypomethylation and hypermethylation. 
Hypomethylation was reported to be the first to describe the changes of epigenetic in 
human cancer (m5C residues replaced by unmethylated C residues) in 1983 where they 
have observed the alterations of DNA methylation throughout the genome in many 
different cancers against the wide variety of normal tissues (Ehrlich M et al., 1983). 
For instance, a study has well described the hypomethylation of few cancer-irrelevant 
gene regions in colon adenocarcinomas versus normal colonic epithelium where they 
have reported that metastases are more susceptible to cancer-linked DNA than in 
control tumours (Feinberg and Vogelstein, 1983).  
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As for hypermethylation, it is known to be contrast of methylation change where 
it is also one of the most stable aspect of genome of cancer (Rauch et al., 2009). Figure 
2.3 best describes the similarity and differences of hypomethylation and 
hypermethylation of DNA.  
 
 
Figure 2.4 Similarities and differences in cancer-associated hypo- and hyper-
methylation of DNA (Adapted from Ehrlich, 2009) 
 
Figure 2.4 showed that hypomethylation comprises almost half of the genome. 
It is also highly associated with tumour progression or malignancy degree (Ehrlich, 
2006). 
 
 
